Many AD pQTLs in CSF were enriched in neuroimmune activation, suggesting a genetic basis for neuroimmune dysregulation in AD, and how genetic variation shapes protein expression in the central nervous system is highlighted.
Abstract
Despite the identification of numerous genetic risk variants for Alzheimer's disease (AD), mechanisms through which these variants act remain unclear. Identifying specific proteins levels affected by genetic variation can provide valuable insights into the underlying biological pathways implicated in AD. To gain more insight into effects of genetic variation on AD-related processes, we conducted a genome-wide protein pQTL study using untargeted TMT mass spectrometry in cerebrospinal fluid (CSF) of 2,215 proteins across 487 individuals. Replication was assessed in the independent EMIF-AD MBD cohort of 242 individuals. We identified 399 independent CSF pQTL signals (PBonferroni < 2.26 × 10⁻11) associated with 222 proteins, 69% of which were novel. Findings included gene-protein links such as RPS23P10/HSPA6 with CSF FCGR2A, BIN2 with CSF GALNT6, APOE with CSF HS3ST1, and the HLA-region with CSF HLA-DPB1 and PLXDC2. We replicated 230 of 270 gene-protein associations. A proteome-wide association study identified genetically predicted CSF protein levels to be associated with AD, including SIRPA, PLXDC2, and GALNT6. Many AD pQTLs in CSF were enriched in neuroimmune activation, suggesting a genetic basis for neuroimmune dysregulation in AD. This study highlights how genetic variation shapes protein expression in the central nervous system, offering mechanistic insight into AD.
Sequence models predict the molecular effects of genetic variation, yet their contribution to interpreting Alzheimer's disease (AD) association signals remains uncertain. Here we analysed AlphaGenome Atlas predictions for 111,446 common variants across 75 regions from a European-ancestry genome-wide association study (...
Understanding of the genetic architecture of AD in the context of its main genetic driver is improved, and APOE-stratified insights may help understand and overcome side effects, inform clinical trial enrollment strategies, and create the scientific basis for targeted, mechanism-driven therapies in neurodegenerative di...
J. Thomassen, H. Leonard, Brittany Ulms et al.· Nature Genetics· 0 citations
The first pathway resolved South Asian genetic profile and a framework for comparative studies across populations are provided, with different contributions from P/LP-associated and VUS associated gene sets.
R. Menon, A. I. Khan, D. Elangovan et al.· medRxiv· 0 citations
The AD-specific transcriptomic risk scores (TRSs) developed in this study shows promising clinical utility in AD diagnosis, differential diagnosis, and risk prediction, providing valuable translational medical evidence for early screening and precision prevention of Alzheimer's disease.
Peng-Fei Zhang, Zhongqian Juan, Jia-Lin Han et al.· European Archives of Psychia...· 0 citations
Leveraging multi-omics to better understand the molecular signatures and pathways underlying Alzheimer’s disease (AD) pathogenesis is critical for early diagnosis and disease modifying interventions. We performed peripheral blood transcriptome (N = 669) and epigenome microarray analyses (N = 553) on non-Hispanic white...
Brendan A. Mitchell, I. Hausle, Sarah Smith et al.· npj Dementia· 0 citations
Alzheimer’s disease (AD) is a genetically complex disorder in which inherited susceptibility is distributed across rare high-impact variants, the apolipoprotein E (APOE) locus, and a broad polygenic background of common risk alleles. Polygenic risk scores (PRSs) provide a quantitative framework for summarizing this dis...
Efthalia Angelopoulou, Ioannis Stamelos, Stefanos N. Sampatakakis et al.· Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.